Welcome to Amber, pioneers in hyper-early disease detection
IR + Plasmonics + AI
info@amberhs.com
info@amberhs.com
IR + Plasmonics + AI
Accurately detecting multiple chronic diseases from a single test is a critical challenge in modern medicine. Amber HS is revolutionizing this paradigm with an innovative technology platform designed to overcome the limitations of current methods.
We use mid-infrared spectroscopy enhanced with plasmonic nanoparticles to analyse liquid biopsies.
Detecting a disease in its early stages significantly increases the probability of a cure.
We only require a small blood sample for a complete analysis.
We identify diseases before clinical symptoms appear.
A single analysis can detect various types of cancer and chronic diseases.
Our technology provides a cutting-edge framework to screen for multiple diseases. We use liquid biopsy analysis powered by plasmonic-enhanced IR technology and statistical machine learning.
Early disease detection is key to halting its progression, making treatments more effective, increasing the chances of a cure, and improving quality of life.
At Amber, we don’t just develop technology; we create life-improving solutions. Our team of experts, consisting of engineers, physicists, mathematicians, and biologists, works tirelessly to expand detection capabilities, including new types of cancer.
With each breakthrough, we move closer to our goal: to give people the power to understand and control their health like never before.
— Amber Health Team —
Receive the latest news on our research breakthroughs.
Discover the latest progress in our research projects, scientific milestones, and updates
